Dynavax Technologies Corp
DVAX15.500USD
+0.010+0.06%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.82BMarket Cap
LossP/E TTM
More Details of Dynavax Technologies Corp Company
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Dynavax Technologies Corp Info
Ticker SymbolDVAX
Company nameDynavax Technologies Corp
IPO dateFeb 19, 2004
CEOSpencer (Ryan)
Number of employees405
Security typeOrdinary Share
Fiscal year-endFeb 19
Address2100 Powell Street
CityEMERYVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94608
Phone15108485100
Websitehttps://www.dynavax.com/
Ticker SymbolDVAX
IPO dateFeb 19, 2004
CEOSpencer (Ryan)
Company Executives of Dynavax Technologies Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Ryan Spencer
Mr. Ryan Spencer
Chief Executive Officer, Director
Chief Executive Officer, Director
396.09K
+118415.00%
Mr. David F. Novack
Mr. David F. Novack
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
109.97K
--
Dr. Robert (Rob) Janssen, M.D.
Dr. Robert (Rob) Janssen, M.D.
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
74.92K
--
Mr. John L. Slebir
Mr. John L. Slebir
Senior Vice President, General Counsel
Senior Vice President, General Counsel
63.47K
+32056.00%
Ms. Kelly MacDonald, CPA
Ms. Kelly MacDonald, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
56.49K
+30977.00%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
29.86K
+5758.00%
Dr. Peter R. Paradiso, Ph.D.
Dr. Peter R. Paradiso, Ph.D.
Independent Director
Independent Director
24.83K
+5758.00%
Dr. Daniel L. (Dan) Kisner, M.D.
Dr. Daniel L. (Dan) Kisner, M.D.
Independent Director
Independent Director
23.33K
+5758.00%
Mr. Brent MacGregor
Mr. Brent MacGregor
Independent Director
Independent Director
21.83K
+5758.00%
Mr. Joseph Metzinger
Mr. Joseph Metzinger
Vice President, Chief Accounting Officer
Vice President, Chief Accounting Officer
7.13K
+7129.00%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Ryan Spencer
Mr. Ryan Spencer
Chief Executive Officer, Director
Chief Executive Officer, Director
396.09K
+118415.00%
Mr. David F. Novack
Mr. David F. Novack
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
109.97K
--
Dr. Robert (Rob) Janssen, M.D.
Dr. Robert (Rob) Janssen, M.D.
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
74.92K
--
Mr. John L. Slebir
Mr. John L. Slebir
Senior Vice President, General Counsel
Senior Vice President, General Counsel
63.47K
+32056.00%
Ms. Kelly MacDonald, CPA
Ms. Kelly MacDonald, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
56.49K
+30977.00%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
29.86K
+5758.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
HEPLISAV-B
89.95M
94.81%
Other revenue
4.92M
5.19%
By RegionUSD
Name
Revenue
Proportion
US
94.69M
99.81%
Non-US
183.00K
0.19%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
HEPLISAV-B
89.95M
94.81%
Other revenue
4.92M
5.19%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Deep Track Capital LP
13.83%
BlackRock Institutional Trust Company, N.A.
12.93%
The Vanguard Group, Inc.
7.04%
State Street Investment Management (US)
5.53%
Millennium Management LLC
3.98%
Other
56.68%
Shareholders
Shareholders
Proportion
Deep Track Capital LP
13.83%
BlackRock Institutional Trust Company, N.A.
12.93%
The Vanguard Group, Inc.
7.04%
State Street Investment Management (US)
5.53%
Millennium Management LLC
3.98%
Other
56.68%
Shareholder Types
Shareholders
Proportion
Investment Advisor
35.91%
Hedge Fund
35.76%
Investment Advisor/Hedge Fund
22.50%
Research Firm
6.27%
Pension Fund
1.19%
Individual Investor
0.84%
Bank and Trust
0.37%
Private Equity
0.04%
Sovereign Wealth Fund
0.03%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
546
115.83M
109.38%
+66.95K
2025Q3
565
115.78M
113.44%
+813.17K
2025Q2
563
116.95M
120.36%
-13.51M
2025Q1
558
131.20M
118.77%
-16.39M
2024Q4
550
133.28M
116.08%
-4.50M
2024Q3
545
132.56M
115.53%
-2.40M
2024Q2
531
134.71M
114.10%
-1.03M
2024Q1
527
135.87M
107.19%
-4.14M
2023Q4
514
128.04M
106.45%
-253.89K
2023Q3
500
128.23M
106.72%
-886.82K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Deep Track Capital LP
15.73M
13.83%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
14.70M
12.93%
-1.10M
-6.96%
Sep 30, 2025
The Vanguard Group, Inc.
8.08M
7.11%
-327.20K
-3.89%
Sep 30, 2025
State Street Investment Management (US)
6.29M
5.53%
-110.47K
-1.73%
Sep 30, 2025
Millennium Management LLC
4.53M
3.98%
+2.92M
+180.74%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
3.57M
3.14%
-77.23K
-2.12%
Sep 30, 2025
Chicago Capital, LLC
4.31M
3.79%
-919.11K
-17.58%
Sep 30, 2025
Renaissance Technologies LLC
3.14M
2.76%
+252.02K
+8.73%
Sep 30, 2025
Two Sigma Investments, LP
3.01M
2.65%
-784.25K
-20.67%
Sep 30, 2025
Geode Capital Management, L.L.C.
2.53M
2.23%
-158.37K
-5.89%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Biotechnology & Genome ETF
2.91%
Virtus LifeSci Biotech Products ETF
1.58%
ETC 6 Meridian Small Cap Equity ETF
1.21%
Invesco S&P SmallCap Health Care ETF
0.62%
ETC 6 Meridian Low Beta Equity Strategy ETF
0.46%
Pacer US Small Cap Cash Cows Growth Leaders ETF
0.42%
State Street SPDR S&P Biotech ETF
0.41%
Themes US Small Cap Cash Flow Champions ETF
0.35%
Royce Quant Small-Cap Quality Value ETF
0.29%
Direxion Daily S&P Biotech Bull 3X Shares
0.25%
View more
Invesco Biotechnology & Genome ETF
Proportion2.91%
Virtus LifeSci Biotech Products ETF
Proportion1.58%
ETC 6 Meridian Small Cap Equity ETF
Proportion1.21%
Invesco S&P SmallCap Health Care ETF
Proportion0.62%
ETC 6 Meridian Low Beta Equity Strategy ETF
Proportion0.46%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proportion0.42%
State Street SPDR S&P Biotech ETF
Proportion0.41%
Themes US Small Cap Cash Flow Champions ETF
Proportion0.35%
Royce Quant Small-Cap Quality Value ETF
Proportion0.29%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.25%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
